Objective    To evaluate and the effects and safety of gemcitabine plus carboplatin (GEM+CBP) regimen and navebine plus cisplatin (NVB+DDP) regimens for aged patients with advanced non-small cell lung cancer (NSCLC).     Methods    The 60 cases of aged patients with NSCLC

over 65 years old and 35 cases beyond 70

were randomly and equally divided into 2 groups. Group A received 1 000 mg/m

2

GEM at day 1 and 8

and 300 mg/m

2

CBP at day 1. Group B underwent the therapy of 25 mg/ m

2

NVB at day 1 and 8

and 80 mg/m

2

DDP at day 1 and 3. Both were treated with 3 weeks as a cycle.     Results    Overall response rate was 43.3% in group A and 36.7% in group B without significant difference. The median survival time (MST) and disease median response  time(DPT) was 9.2 and 4.4 months in A group

and 8.9 and 4.2 months in B group. MST

DPT and one year survival rate were similar in 2 groups. Toxicities: WHO grade Ⅲ/Ⅳ leukopenia occurred in  B group  was  higher than that in  A group. The frequence of phlebitis was significantly higher in group  B than group A (P0.05).     Conclusion    There are similar outcomes in the overall response rates

MST

DRT and one year survival rate in 2 groups

but GEM+CBP regimen has a better tolerability and lower toxicities. GEM+CBP regimen is a better  chemotherapeutic regimen for aged NSCLC patients.